journal article·2018-07-04Open access

MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9

Yebin Lu, Ling Tang, Qi Zhang, Zhipeng Zhang, Wei Wei

Abstract

MicroRNAs (miRNAs) play an important role in the development and progression of human malignancy. miR-613, as a tumour suppressor, was reported to decrease in several tumours. However, the expression levels and role of miR-613 in gastric cancer remain unknown. In this study, we found that miR-613 was evidently downregulated in gastric cancer tissue and cell. The functional analysis showed that miR-613 suppressed cell proliferation and migration in gastric cancer. Next, the dual-luciferase reporter system supported CDK9 as a direct target gene of miR-613. miR-613 mimics evidently repressed CDK9 expression in gastric cancer cells. Furthermore, we found that CDK9 in upregulated in gastric cancer and the CDK9 expression levels were inversely correlated with that of miR-613 in gastric cancer tissues. Overall, the results revealed that miR-613, as a tumour suppressor, involves in gastric cancer progression and metastasis by targeting CDK9, implying a novel potential therapeutic target for the treatment of gastric cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · RNA modifications and cancer · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China;

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

References (29)

Show source-provided references
1. 10.3109/21691401.2016.116770110.3109/21691401.2016.1167701 ↗
2. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
3. 10.1080/21691401.2016.119836110.1080/21691401.2016.1198361 ↗
4. 10.1007/s13277-013-0808-x10.1007/s13277-013-0808-x ↗
5. 10.1038/nrg347110.1038/nrg3471 ↗
6. 10.4149/neo_2014_05610.4149/neo_2014_056 ↗
7. 10.1007/s13277-015-3379-110.1007/s13277-015-3379-1 ↗
8. 10.3892/ijo.2014.257110.3892/ijo.2014.2571 ↗
9. 10.18632/oncotarget.605910.18632/oncotarget.6059 ↗
10. Li C · Oncotarget · 2016 · 7 · 6698910.18632/oncotarget.11888 ↗
11. 10.18632/oncotarget.1318210.18632/oncotarget.13182 ↗
12. 10.1007/s13277-015-4507-710.1007/s13277-015-4507-7 ↗
13. 10.1007/s13277-015-4271-810.1007/s13277-015-4271-8 ↗
14. Li B · Am J Transl Res · 2016 · 8 · 5475
15. 10.1007/s13402-015-0262-410.1007/s13402-015-0262-4 ↗
16. Li X · Am J Cancer Res · 2016 · 6 · 2869
17. 10.1016/j.bbrc.2015.12.05410.1016/j.bbrc.2015.12.054 ↗
18. 10.1016/j.bbrc.2016.07.03110.1016/j.bbrc.2016.07.031 ↗
19. Zhang Y · Tumour Biol · 2017 · 39
20. 10.1007/s00535-013-0851-910.1007/s00535-013-0851-9 ↗
21. 10.4238/2015.December.23.1910.4238/2015.December.23.19 ↗
22. 10.1038/bjc.2011.31110.1038/bjc.2011.311 ↗
23. 10.1128/MCB.23.15.5165-5173.200310.1128/MCB.23.15.5165-5173.2003 ↗
24. 10.1210/me.2010-023810.1210/me.2010-0238 ↗
25. 10.2174/13816121280067275010.2174/138161212800672750 ↗
26. 10.18632/oncotarget.699710.18632/oncotarget.6997 ↗
27. 10.1080/15384101.2016.113818610.1080/15384101.2016.1138186 ↗
28. 10.1158/1535-7163.MCT-13-084910.1158/1535-7163.MCT-13-0849 ↗
29. 10.1002/ijc.2612710.1002/ijc.26127 ↗